Latest News

Costs of Malignant Blood Disorders in European Countries Reached €23 Billion in 2012

Costs of Malignant Blood Disorders in European Countries Reached €23 Billion in 2012

Blood disorders, particularly malignant cancers, represent an enormous economic burden to the European economy, and to "society overall."

Achieving Negative Margin Essential for Optimizing Local Control, Survival in Sarcoma

Achieving Negative Margin Essential for Optimizing Local Control, Survival in Sarcoma

Achieving a negative margin may be essential for optimizing both local control and survival in patents with soft tissue sarcoma treated with radiotherapy.

FDA Declines to Approve Pegfilgrastim Biosimilar

FDA Declines to Approve Pegfilgrastim Biosimilar

The U.S. Food and Drug Administration (FDA) denied approval to the biosimilar pegfilgrastim candidate developed by Sandoz.

Nivolumab Active After Both Auto-HSCT, Brentuximab Vedotin in Hodgkin Lymphoma

Nivolumab Active After Both Auto-HSCT, Brentuximab Vedotin in Hodgkin Lymphoma

Nivolumab induced frequent responses with an acceptable safety profile for patients with classical Hodgkin lymphoma.

Geographic Location May Be Linked to Risk of Basal Cell Carcinoma

Geographic Location May Be Linked to Risk of Basal Cell Carcinoma

Geographic location may be a causal factor for the development of basal cell carcinoma (BCC).

TK216 Granted Orphan Drug Designation for Treatment of Ewing Sarcoma

TK216 Granted Orphan Drug Designation for Treatment of Ewing Sarcoma

The U.S. Food and Drug Administration granted Orphan Drug Designation to TK216 for the treatment of Ewing sarcoma.

Filanesib With Bortezomib and Dexamethasone Active in Myeloma

Filanesib With Bortezomib and Dexamethasone Active in Myeloma

The combination of filanesib, bortezomib, and dexamethasone appears to have durable activity in multiple myeloma.

Aldoxorubicin May Be Effective for Treatment of Soft Tissue Sarcoma

Aldoxorubicin May Be Effective for Treatment of Soft Tissue Sarcoma

Aldoxorubicin may be more efficacious for the treatment of soft tissue sarcoma (STS).

Vaccines, Immunotherapy May Enhance Survival of Patients With NSCLC

Vaccines, Immunotherapy May Enhance Survival of Patients With NSCLC

Tumor vaccines and cellular immunotherapies may improve overall and progression-free survival of patients with non-small cell lung cancer (NSCLC).

High-fat Mediterranean Diet Protective Against Breast Cancer, Diabetes

High-fat Mediterranean Diet Protective Against Breast Cancer, Diabetes

Even a high-fat Mediterranean diet may protect against breast cancer, diabetes, and cardiovascular disease.

Metastatic Prostate Cancer Cases On the Rise in the U.S.

Metastatic Prostate Cancer Cases On the Rise in the U.S.

New cases of metastatic prostate cancer in the United States have increased 72 percent in the past decade.

GOYA Study of G-CHOP Fails to Meet Primary End Point

GOYA Study of G-CHOP Fails to Meet Primary End Point

The phase 3 GOYA study for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) failed to meet its primary endpoint.

Ceritinib Induces Durable Responses in Pretreated Patients

Ceritinib Induces Durable Responses in Pretreated Patients

Treatment with ceritinib induced responses in patients with ALK­-rearranged non-small cell lung cancer (NSCLC).

Veliparib and Carboplatin May Be Effective Against Triple-negative Breast Cancer

Veliparib and Carboplatin May Be Effective Against Triple-negative Breast Cancer

Veliparib and carboplatin may together be an effective treatment for patients with clinical stage II or II breast cancer.

PD-1 Immunotherapy Resistance Linked With Pathway Defects

PD-1 Immunotherapy Resistance Linked With Pathway Defects

Acquired resistance to PD-1 blockade immunotherapy of patients with melanoma may be associated with defects in the pathways.

Antipsychotic Drug Olanzapine Prevents Nausea for Patients Receiving Chemotherapy

Antipsychotic Drug Olanzapine Prevents Nausea for Patients Receiving Chemotherapy

Dopamine antagonist olanzapine prevents nausea and the complete response rate among previously untreated patients receiving highly emetogenic chemotherapy.

Ipilimumab Feasible for Patients Who Relapse After Stem-cell Transplantation

Ipilimumab Feasible for Patients Who Relapse After Stem-cell Transplantation

Administration of the anti-CTLA-4 antibody ipilimumab is feasible for patients with recurrent hematologic malignancies.

Monoclonal Gammopathy and PADI2 Expression May Be Linked to Risk of Multiple Myeloma

Monoclonal Gammopathy and PADI2 Expression May Be Linked to Risk of Multiple Myeloma

Researchers may have detected a gene that, if targeted by a drug, may increase the effectiveness of multiple myeloma (MM) treatment.

Papular, Nodular Eruptions Frequent With Anti-PD1/PD-L1 Therapy

Papular, Nodular Eruptions Frequent With Anti-PD1/PD-L1 Therapy

Many patients with advanced cancer receiving anti-PD-1 or anti-PD-L1 treatment have papular and nodular eruptions with scale with lichenoid features.

TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters